De novo genetic variation is an important class of risk factors for autism spectrum disorder (ASD). Recently, whole-exome sequencing of ASD families has identified a novel de novo missense mutation in the human dopamine (DA) transporter (hDAT) gene, which results in a Thr to Met substitution at site 356 (hDAT T356M). The dopamine transporter (DAT) is a presynaptic membrane protein that regulates dopaminergic tone in the central nervous system by mediating the high-affinity reuptake of synaptically released DA, making it a crucial regulator of DA homeostasis. Here, we report the first functional, structural and behavioral characterization of an ASD-associated de novo mutation in the hDAT. We demonstrate that the hDAT T356M displays anomalous function, characterized as a persistent reverse transport of DA (substrate efflux). Importantly, in the bacterial homolog leucine transporter, substitution of A289 (the homologous site to T356) with a Met promotes an outward-facing conformation upon substrate binding. In the substrate-bound state, an outward-facing transporter conformation is required for substrate efflux. In Drosophila melanogaster, the expression of hDAT T356M in DA neurons-lacking Drosophila DAT leads to hyperlocomotion, a trait associated with DA dysfunction and ASD. Taken together, our findings demonstrate that alterations in DA homeostasis, mediated by aberrant DAT function, may confer risk for ASD and related neuropsychiatric conditions.
INTRODUCTION
Genetic factors have been implicated as important components in the etiology of autism spectrum disorder (ASD). It is now accepted that rare genetic variation affecting single nucleotides of proteincoding DNA as well as rare genomic copy number variants are significant ASD risk factors. [1] [2] [3] [4] In particular, increasing evidence suggests that de novo genetic variation is a risk factor in ASD and other neuropsychiatric diseases. 1, 3, [5] [6] [7] Several groups have conducted whole-exome sequencing on ASD families, and collectively, these studies indicate that discrete de novo mutation (singlenucleotide variation or small indels) contribute to the overall genetic risk of ASD. 2, [8] [9] [10] Among these variations is the first ASD-associated, de novo mutation found in the human dopamine (DA) transporter (hDAT) gene (SLC6A3). 8 This mutation results in a Thr to Met substitution at position 356 (hDAT T356M). The consequences of this de novo mutation and its impact on DA neurotransmission have yet to be elucidated.
The neurotransmitter DA has an important role in the central nervous system by regulating a variety of functions, including motor activity, motivation, attention and reward. [11] [12] [13] [14] Disrupted DA function is implicated in a number of neuropsychiatric disorders, including bipolar disorder, schizophrenia, attentiondeficit hyperactivity disorder (ADHD) [15] [16] [17] and, more recently, ASD. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The dopamine transporter (DAT) is a presynaptic membrane protein that regulates DA neurotransmission via the high-affinity reuptake of synaptically released DA. 28 It is the major molecular target of cocaine (COC), amphetamine (AMPH; Adderall) and methylphenidate (Ritalin). [29] [30] [31] [32] [33] Owing to DAT's role in DA neurotransmission, SLC6A3 variants have been a focus of genetic association studies linking the etiology of brain disorders to dysregulated DA neurotransmission. 34, 35 Recent studies have identified a rare, inherited, functional missense SLC6A3 variant, hDAT A559V (rs28364997), 36, 37 that has been associated with ADHD, which is commonly comorbid in ASD subjects. [38] [39] [40] [41] These studies point to a contribution of DAT genetic variants in complex brain disorders.
Although the role of DA in ADHD has been established, 42 DA's role in ASD is poorly understood. 43 Many individuals with ASD exhibit co-occurrence of ADHD symptoms (B20-45%). [44] [45] [46] [47] The comorbid nature of ADHD with ASD points to dysregulation of common signaling pathways (for example, DA) as a mechanism underlying these neuropsychiatric disorders. 48 Here, we characterized the first ASD-identified, de novo mutation in hDAT by presenting structural, functional and behavioral analysis of this de novo variant. These results implicate altered DA homeostasis as a potential liability in ASD risk.
MATERIALS AND METHODS

Subjects and clinical assessment
Subjects from this family included the proband, both parents and unaffected sibling, who were recruited by the Boston Autism Consortium as described previously. 8, 49 Clinical assessment followed standard research criteria for ASD diagnosis. The proband was classified as having a comparatively 'narrow' diagnosis (as opposed to a 'broader ASD') on the basis of diagnostic algorithms from the Autism Diagnostic Interview Revised (ADI-R) 50 using criteria described by Risi et al., 51 and classification resulting from the diagnostic algorithm of the Autism Diagnostic Observational Session. 52 Proband IQ was assessed at age 5 years, 9 months using the Wechsler Preschool and Primary Scale of Intelligence (WPPSI; Wechsler, D. (1967)). The Social Responsiveness Scale (Western Psychological Services) was performed on both parents to index the presence and severity of broader autism phenotype traits, followed by medical and family history provided by the biological mother.
SLC6A3 T356M de novo discovery
Methodological details and validation of the de novo mutation are published. 8 Briefly, DNA derived from whole blood of both parents and the probands was subjected to whole-exome sequence analysis. The T356M variant, identified as a heterozygote in the proband and absent in both parents, was experimentally validated and confirmed to be a de novo mutation that does not appear in the unaffected sibling.
Cell culture and transfection
The GFP-hDAT-pCIHygro expression vectors containing either hDAT or hDAT T356M sequence were generated, confirmed and transiently transfected into Chinese hamster ovary cells using FuGENE-6 (Promega, Fitchburg, WI, USA). Assays were conducted 24-48 h post-transfection.
Amperometry and patch clamp electrophysiology hDAT and hDAT T356M cells were plated at a density of B30,000 per 35-mm culture dish and experiments were conducted as previously described. 53, 54 [ 3 H]DA uptake hDAT and hDAT T356M cells were seeded (50,000 cells per well) into polyornithine coated, 24-well plates, 48 h before assaying. Uptake kinetic assays were performed as described in the supplementary information of Rickhag et al. 55 and in Rasmussen et al.
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AMPH uptake
Plated hDAT and hDAT T356M cells were washed with KRH (Krebs-Ringer-HEPES) buffer and incubated for 5 min at 37 1C with 10 nM AMPH. Cells were washed three times with ice-cold KRH. AMPH was quantified using a HPLC system previously described. 57 Cell surface biotinylation and western blot
For cell surface biotinylation assays and western blots, hDAT and hDAT T356M cells were cultured in six-well plates and experiments were conducted as in Mazei-Robinson et al.
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Homology modeling of hDAT and construction of the T356M simulation system
As the template, the homology model uses the known crystal structure for the cognate and homologous structure of the recent outward-open crystal structure of leucine transporter (LeuT). 58 The substrate DA, two Na þ ions and a Cl -ion were positioned as described in Shan et al. 59 To model the mutant hDAT construct with T356M, the mutation was introduced using the free energy perturbation method. 60 Double electron electron resonance Cysteine residues were introduced using site-directed mutagenesis into LeuT and LeuT A289M constructs. 61 Experiments were conducted as in Claxton et al. 61 In Figure 4 , Apo refers to ion Na þ and leucine-free transporter, whereas the þ NaL state was obtained by the addition of 200 mM NaCl and fourfold molar excess of Leu relative to LeuT. Double electron electron resonance 62 was performed at 83 K on a Bruker 580 pulsed electron paramagnetic resonance spectrometer operating at Q-band frequency using a standard 4-pulse sequence. 63 Double electron electron resonance echo decays were analyzed to obtain distance distributions. 64 
Drosophila genetics
Drosophila homozygotes for the DAT null allele DAT fmn (dDAT KO) 65 and flies harboring TH-Gal4 66 were outcrossed to a control line (Bloomington Indiana) 6326) and selected by PCR or eye color. TH-GAL4 (Bl 8848) and M{vas-int.Dm}ZH-2A, M{3xP3-RFP.attP 0 } ZH-22A (Bl 24481) were obtained from the Bloomington Indiana stock center and outcrossed to dDAT KO flies carrying the white (w 1118 ) mutation (Bloomington Indiana stock number 6236) for 5-10 generations. Transgenes (hDAT or hDAT T356M) were cloned into pBI-UASC 67 and constructs were injected into embryos from M{vas-int.Dm}ZH-2A, M{3xP3-RFP.attP 0 }ZH-22A (Bl 24481). Initial potential transformants were isolated and selected.
Behavioral analysis
Three days post eclosion, male Drosophila were collected and placed into tubes with food for 72 h. Locomotion was recorded by beam breaks and analyzed using equipment/software from Trikinetics (www.trikinetics.com). For the AMPH-induced locomotion, males were starved for 6 h and then fed sucrose (5 mM) containing either AMPH (10 mM) or vehicle. Data were analyzed by one-way analysis of variance followed by a Newman-Keuls Multiple Comparison Post-test.
RESULTS
T356M de novo DAT variant has impaired function
A recent study assessed the role of de novo variation in ASD by using whole-exome sequencing in 175 ASD parent-child trios. 8 In this study, a de novo SLC6A3 variant was identified, resulting in a Thr to Met substitution at site 356. 8 Given the rarity of non-synonymous de novo events, it is not surprising that this mutation was absent in the B1000 unrelated ASD cases and controls 8 and has not been deposited in 1000 genomes, 68 single-nucleotide polymorphism database (build 137), 69 or the NHLBI (National Heart, Lung, and Blood Institute) Exome Sequencing Project. The subject carried no other coding de novo mutations. The T356 is completely conserved across several species ( Figure 1a) . Importantly, the T356 residue is located in the seventh transmembrane domain of hDAT and resides in a highly conserved region implicated in ion binding. 70 The molecular modeling of hDAT and in silico mutagenesis of T356 is shown in Figure 1b .
The subject harboring this de novo mutation is the elder male child of healthy nonconsanguineous Caucasian parents (proband has a healthy younger sibling). There is no immediate family history of ASD or related psychiatric conditions. The subject has a normal IQ (94) and has no history of seizures or other comorbidites. By the age of 6 years, the proband was diagnosed with ASD (see Supplementary Material for full clinical reports).
To evaluate whether the T356M variant may be a risk factor in the proband's ASD, we compared the activities of hDAT and hDAT T356M in a heterologous expression system. We examined radioactive [ 3 H]DA uptake and affinity. In hDAT T356M cells, the maximal velocity of DA influx (V max ) was significantly reduced, whereas the apparent DA affinity (K m ) of hDAT T356M was not significantly different from that of hDAT (Figure 2a, top) . A representative plot of DA uptake kinetics for hDAT and hDAT T356M is shown in Figure 2a In an equilibrated three-dimensional homology model of hDAT, the T356M mutation is located on transmembrane domain 7 (TM7). Top: schematic views representing a 1801 rotation show T356M with respect to the TM helices. TM7 is shown in dark blue. Bottom: critical residues that interact with dopamine (DA) 79, 80 are shown, as well as the bound Na þ and Cl À ions. The methionine is rendered together at position 356 with the wild-type threonine (green).
fraction, respectively. The total fraction for hDAT and hDAT T356M contained both glycosylated and non-glycosylated forms of the DAT. Surface fractions were quantitated, normalized to total DAT (glycosylated) and expressed as a percent of hDAT (Figure 2b ; bottom). Furthermore, normalizing the total DAT fraction (glycosylated) to actin-loading control yielded no significant differences between hDAT and hDAT T356M total expression (data are expressed as a percentage of hDAT; hDAT 100 ± 17.6% versus hDAT T356M 96.4 ± 13.7%; PX0.87 by Student's t-test; n ¼ 8-11).
hDAT T356M displays anomalous DA efflux Although hDAT T356M displays similar surface expression to that of hDAT, it demonstrates reduced ability to accumulate intracellular DA. One possibility is that constitutive DA efflux, here referred to as anomalous DA efflux (ADE), contributes to this reduced DA uptake in the hDAT T356M cells. This efflux would impede the intracellular accumulation of DA.
To determine whether hDAT T356M exhibits ADE, cells were whole-cell patch clamped and perfused for 10 min with an internal solution containing 2 mM DA. 53 The electrode, in current clamp configuration, allows the cell to control its membrane voltage. In addition, this technique ensures that cells expressing either hDAT or hDAT T356M were equally loaded with DA. DA efflux was quantified through amperometry. 53 We have previously shown that, in the presence of ADE, COC decreases the amperometric signal through blockade of DAT. 54 In hDAT cells, amperometric currents were unaffected by the application of COC (Figure 3a , top, hDAT, COC), indicating no ADE. In contrast, amperometric signals from hDAT T356M cells were significantly reduced by the application of COC (Figure 3a , top, hDAT T356M, COC), revealing ADE. hDAT T356M-expressing cells displayed a significant increase in ADE compared with hDAT-transfected cells (Figure 3a, bottom) .
Cell membrane depolarization has been shown to support DA efflux. 71 Figure 3b reveals that there is not a significant difference in resting membrane potential (measured in current clamp) between cells expressing hDAT or hDAT T356M. This indicates that differences in the function of hDAT and hDAT T356M are not due to resting membrane potential.
Next, we determined possible changes in the ability of AMPH to cause DA efflux by patch delivering DA into hDAT or hDAT T356M cells while recording DA efflux with amperometry. AMPH dose-response assays (measuring the peak of the amperometric current at different AMPH concentrations) revealed that hDAT T356M and hDAT cells have comparable AMPH EC 50 (EC 50 ; hDAT: 0.15 ± 0.05 mM; hDAT T356M: 0.16 ± 0.07 mM; n ¼ 4; pX0.95 by Student's t-test). Then, using a saturating AMPH concentration (10 mM), we determined DA efflux in either hDAT or hDAT T356M cells (Figure 3c, top) . AMPH-induced DA efflux was significantly reduced in hDAT T356M cells in comparison with hDAT cells (Figure 3c ). These results strongly suggest that ADE does not share common mechanisms with AMPH-induced DA efflux.
In LeuT, substitution of Ala289 with a Met promotes an outwardfacing conformation To investigate the structural consequences of the T356M de novo mutation in a DAT homolog with a known crystal structure, we analyzed changes in the conformational cycle of the LeuT. We substituted A289 (the homologous amino acid to T356) with a Met (LeuT A289M). We measured distances between pairs of spin labels (r (Å)) and the distance distribution (P(r), the probability of a given distance between the two labels) monitoring the intra-and extracellular gates by double electron electron resonance. 72 First, we examined the pair 309/480 (Figure 4a , left) that monitors the relative movement of the extracellular loop 4 in LeuT. This loop obstructs the permeation pathway in the Apo conformation, 61 as indicated by the close proximity of the pair 309/480 (Figure 4a , middle, Apo black line). Upon Na þ binding, the distance between extracellular loop 4 and TM12 increases, 61 indicating opening of the extracellular vestibule and enabling substrate access (data not shown). 61 Apo; compare red and black lines) as well as Na þ -bound state (data not shown) are similar in LeuT and LeuT A289M. Yet, LeuT A289M with Na þ and Leu bound in the vestibule has a destabilized bound structure with fluctuations on the extracellular side (Figure 4a , right; þ Na/L; compare red and black lines). The probability distribution in the Na/Leu-bound state contains distinct populations of conformations that indicate fluctuations of LeuT A289M to a permeation pathway that has increased probability to be open to the outside, relative to LeuT (Figure 4a , right; red line, arrows). We then examined the pair 7/86 (Figure 4b , left) to determine the distance between the N-terminus and intracellular loop 1 (IL1) and to monitor fluctuation dynamics on the intracellular side. 72 This is necessary to describe changes in the population of transporters with an inward-facing conformation. 72 In the LeuT background, distance distributions between spin 73 or fluorescent probes 74 in the Apo state are bimodal, reflecting the equilibrium of this intracellular gate between closed and open conformations (Figure 4b , middle; Apo; black lines). Introduction of the A289M leads to a shift in the equilibrium to favor the closed conformation side (Figure 4b , middle; Apo; compare red and black lines, arrow). Na þ binding does not alter the equilibrium between the two conformations (data not shown), whereas Na þ and Leu binding resets this shift to LeuT-like conformations (Figure 4b , middle; þ Na/L; compare red and black lines).
Our results demonstrate that, because of the A289M, the presence of substrate and Na þ fails to completely close the extracellular pathway as in LeuT, inducing fluctuations on the extracellular side. These fluctuations to an open-to-the-outside permeation pathway persist, possibly enabling substrate release. This is in contrast to LeuT, where substrate binding closes the extracellular permeation pathway.
Drosophila expressing hDAT T356M in DA neurons are hyperactive Locomotion is an elemental behavior regulated across species, including Drosophila melanogaster, by DA. [75] [76] [77] Thus, locomotion in flies offers a powerful model for elucidating the behavioral impact of ADE associated with hDAT T356M.
We expressed hDAT or hDAT T356M in flies homozygous for the Drosophila DAT null allele, DAT fmn (dDAT KO), 65 using the Gal4/ UAS system to express a single copy of hDAT or hDAT T356M in a dDAT fmn mutant background, selectively in DA neurons. 78 To generate the transgenic flies, we used phiC31-based integration, which leads to the expression of comparable levels of mRNA for the relevant transgenes (hDAT or hDAT T356M). Locomotion was quantitated by beam crossing detection over a 424-h period (data binned in 15 min intervals) during both the light (horizontal white bar) and dark (horizontal black bar) cycle. Although dDAT KO are hyperactive, 65 flies expressing hDAT in DA neurons have reduced locomotion as compared with dDAT KO, demonstrating the behavioral significance of our approach (Figure 5a , compare hDAT with dDAT KO).
We hypothesized that flies harboring the hDAT T356M would be hyperactive with respect to hDAT-expressing flies owing to an increase in extracellular DA promoted by ADE. This is shown in Figure 5a . Figure 5b shows total (24 h) locomotor activity in the different fly lines. Total activity (24 h) of hDAT T356M and dDAT KO flies is significantly higher than hDAT flies (Figure 5b) .
hDAT T356M cells display compromised AMPH-induced DA efflux (Figure 3c ). This suggests a reduced ability of AMPH to increase locomotion in flies expressing hDAT T356M. Changes in locomotion were determined upon AMPH or vehicle exposure (15 min) and calculated as beam crosses. We observed no significant increase in locomotion in hDAT T356M flies when exposed to AMPH as compared with vehicle control (hDAT T356M (vehicle) 9.7 ± 0.7 beam breaks versus hDAT T356M (AMPH) 12.7 ± 1.6 beam breaks; n ¼ 24; PX0.05). This is in contrast to flies expressing hDAT, where AMPH induced a significant increase in locomotion (hDAT (vehicle) 6.2±0.9 beam breaks versus hDAT (AMPH) 18.2 ± 1.0 beam breaks; n ¼ 24; Pp0.001). Moreover, in the dDAT KO flies, similar to the hDAT T356M flies, AMPH failed to induce a significant increase in locomotion (data not shown).
DISCUSSION
Alterations in DA tone underlie multiple neuropsychiatric disorders, including bipolar disorder, schizophrenia and ADHD. [15] [16] [17] With respect to ADHD, altered DA signaling, including changes in DAT function, may contribute to the cognitive and hyperactive traits of the disorder. 53, 54 ASD, like ADHD, is phenotypically and etiologically complex. However, there is mounting evidence that risk for ASD resides, at least in part, in dopaminergic factors. Variants in DA receptor sub-type genes, including DRD1, DRD3 and DRD4, have been associated with increased risk for ASD 21 as well as with specific phenotypic behavior within ASD. These include repetitive or stereotyped behaviors, [22] [23] [24] oppositional defiant disorder and separation anxiety disorder. 24 Male children carrying four tandem repeats in the promoter region of the MAOA gene (the gene product responsible for degrading amine neurotransmitters, including DA) showed elevated risk for developing ASD. 27 It must be noted that none of these genes are significant in genome-wide association studies of ASD. However, in positron emission tomography studies in adults with ASD, DAT binding was significantly elevated in the orbitofrontal cortex. 18 Genes harboring de novo events are highly significant for understanding the etiology of ASD. 8 This is not surprising as the rate of reproduction is typically low in individuals with autism. Consequently, genetic variants would be subject to negative selection. 1 This suggests that the biological networks identified from these de novo events, and the broader pathways they function within, are candidate risk factors for ASD. In this study, we examine the functional, structural and behavioral consequences of the first identified de novo hDAT missense variant associated with ASD.
Our amperometric recordings demonstrate that the de novo hDAT T356M mutation confers COC sensitive ADE. We also show that ADE does not share common mechanisms with AMPHinduced DA efflux, as hDAT T356M has an impaired AMPH response. It is intriguing to speculate that anomalous transportermediated neurotransmitter efflux may be an unappreciated source of risk for mental illness, especially in disorders associated with altered DA signaling. It is possible that ADE, driven by DAT variants or variants in other genes in the DAT regulatory network (such as DA receptor subtypes), could impact risk for ASD. A similar point for ADE has been argued previously, in the context of ADHD, for the hDAT variant A559V, in its functional identification 54 and original characterization. 53 The question remains as to how the hDAT T356M de novo mutation perturbs transporter structure to trigger ADE. As the crystal structure of hDAT is unavailable, we analyzed changes in the conformational cycle of the hDAT bacterial homolog, LeuT. In LeuT A289M, we measured the distances between pairs of spin labels monitoring the intra-and extracellular gates by double electron electron resonance. The spin labels monitoring the extracellular gate clearly show that in LeuT A289M, in contrast to LeuT, the presence of Na þ and leucine promotes a permeation pathway unoccluded to the outside. In terms of transporter function, it is difficult to draw parallels between hDAT T356M and LeuT A289M. Nevertheless, it is compelling to speculate that the mechanism by which the substrate promotes an outward-open conformation in LeuT A289M, could also support the ability of hDAT T356M to promote ADE when cytoplasmic DA is available. This would suggest that the mechanism of ADE for hDAT T356M is distinct from that of hDAT A559V, which is a result of a tonic activation of DRD2 and the downstream kinase CaMKII. 53 Thus, there may be multiple mechanistic routes to promote hDATmediated ADE, and yet ADE might support the comorbid nature of ASD with ADHD.
In an in vivo context, hDAT T356M may alter extracellular DA levels and, as a consequence, increase locomotion. 65 We selectively expressed hDAT T356M specifically in DA neurons of dDAT KO flies. Drosophila expressing hDAT T356M exhibited prominent hyperactivity as compared with Drosophila expressing hDAT. In addition, AMPH has an impaired ability to increase locomotion in hDAT T356M and dDAT KO flies. This might stem from the decreased ability of AMPH to cause DA efflux in hDAT T356M cells.
Here, we report novel and profound functional abnormalities associated with the hDAT de novo mutation T356M, resulting in enhancement of non-vesicular, DAT-dependent DA release, referred to as ADE. Our data raise the possibility that ADE could impact the risk for ASD.
